Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy

Next Previous
Trial Profile

A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efineptakin alfa (Primary) ; DTaP poliovirus vaccine; Hepatitis A vaccine; Hepatitis B vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccines
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Early breast cancer; Gastrointestinal cancer; HER2 positive breast cancer; Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 01 Nov 2023 Planned End Date changed from 28 Feb 2024 to 1 Nov 2023.
  • 01 Nov 2023 Planned primary completion date changed from 28 Feb 2024 to 1 Nov 2023.
  • 01 Nov 2023 Status changed from active, no longer recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top